Part IV Answers – Coding Collaborative Stage and Treatment Data Collection of Non-malignant Primary CNS Tumors

For these exercises, assume that if a treatment is not mentioned, it was not administered.

1. The patient was referred to a neurologist because of a right-side hearing loss and possible acoustic tumor. A CT scan on March 1, 2004, was used to diagnose right acoustic neuroma. On March 31, 20004, the patient had a craniotomy. A protrusion of tumor in the vestibule appeared to come from the cochlea. Facial nerve was spared. The tumor was totally resected, with clear margins.

CS Extension code	Use "Other parts of CNS" schema. Code 05 Benign or borderline brain tumor.
Surgical procedure of primary site	Use surgery codes for Brain 55, Gross total resection (All of the tumor was removed, with no evidence of tumor.)
Surgical margins of primary site	0, No residual tumor
Scope of regional lymph node surgery	9, not applicable
Radiation treatment volume	00, No radiation treatment
Regional treatment modality (radiation)	00, No radiation treatment
Chemotherapy	00, None
Hormone therapy	00, None
Immunotherapy	00, None
Hematologic transplant and endocrine procedures	00, None

2. A 6-year-old boy had severe headaches and vomiting. An MRI on September 13, 2004, was used to diagnose <u>medulloblastoma of the cerebellum</u>. An <u>infratentorial</u> craniotomy was performed on September 28, 2004, and the tumor was removed. Macroscopic and microscopic residual medulloblastoma remained. On November 1, 2004, the patient began a course of carmustine. After completion of chemotherapy, the patient had a bone marrow transplant with donor marrow from his older brother.

CS Extension code	Use "Brain & Cerebral Meninges" schema. Code 11: Infratentorial tumor, confined to cerebellum
Surgical procedure of primary site	Use surgery codes for Brain 40, partial resection (Tumor was removed but visible and microscopic tumor remained.)
Surgical margins of primary site	3, Macroscopic residual tumor (When both microscopic and macroscopic residual tumor remain, use the higher code.)
Scope of regional lymph node surgery	9, not applicable
Radiation treatment volume	00, No radiation treatment.
Regional treatment modality (radiation)	00, No radiation treatment.
Chemotherapy	02, Single agent chemotherapy
Hormone therapy	00, None
Immunotherapy	00, None
Hematologic transplant and endocrine procedures	12, Allogeneic bone marrow transplant (Patient's brother donated the bone marrow.)

3. Patient had <u>CT scan</u> of the head on February 24, 2004, showing a large <u>prolactinoma of the pituitary gland</u>. The patient started on bromocriptine to shrink the tumor in March 2004. The patient had <u>gamma knife surgery</u> on October1, 2004.

OC Futurales and	Has "The way of Advanced Claused and Others
CS Extension code	Use "Thymus, Adrenal Gland and Other
	Endocrine Glands" schema.
	Code: 05 Benign or borderline tumors
Surgical procedure of primary site	Use Surgery codes for "All Other Sites".
	00, None (gamma knife surgery is radiation)
Surgical margins of primary site	8, No primary site surgery
Scope of regional lymph node	0, None
surgery	(None instead of not applicable because
	pituitary is not one of the sites listed in
	FORDS as "not applicable" for lymph node
	surgery.)
Radiation treatment volume	02, Pituitary
Regional treatment modality (radiation)	43, Gamma knife
Chemotherapy	00, None
Hormone therapy	00, None
Immunotherapy	82, Immunotherapy as first course of
	therapy (bromocriptine is a biologic
	response modifier or immunotherapy.)
Hematologic transplant and	00, None
endocrine procedures	OO, NOTIC
endocine procedures	

4. The patient was referred to a neurologist after reporting symptoms of vomiting, muscle weakness on one side of the face, and several episodes of slurred speech. The patient had an MRI on June 3, 2004, that showed a glioma in the brain stem. Through an infratentorial craniotomy, the tumor was removed on June 30, 2004. The pathology report documented microscopic residual <u>subependymal glioma in the fourth ventricle</u> (9383/1). On August 1, 2004 the patient had conformal radiation to the fourth ventricle.

CS Extension code	Use "Brain & Cerebral Meninges" schema. Code 05 Benign
Surgical procedure of primary site	Use sugery codes for Brain 55, Gross total resection (When tumor is removed and only microscopic tumor residual remains, surgery is still considered total resection.)
Surgical margins of primary site	2, Microscopic residual tumor
Scope of regional lymph node surgery	9, Not applicable
Radiation treatment volume	04, Brain limited (The radiation was given to only part of the brain, fourth ventricle.)
Regional treatment modality (radiation)	32, Conformal therapy
Chemotherapy	00, None
Hormone therapy	00, None
Immunotherapy	00, None
Hematologic transplant and endocrine procedures	00, None

5. The patient's symptoms included headaches, double vision, vomiting, and drowsiness. A CT scan on November 1, 2004, showed a growth confined to the <u>pineal gland</u>. The patient had <u>a biopsy</u> of the pineal gland on November 15, 2004, and the tumor pathology was pineocytoma. The patient began beam radiation to the pineal gland on December 8, 2004.

CS Extension code	Use "Thymus Gland and Other Endocrine Glands" schema.
Surgical procedure of primary site	Code 05 Benign and borderline tumors Use surgery codes for "All Other Sites" 00, None, No surgery of primary site (This is not stated to be an "excisional biopsy" which would be coded "27". Stereotactic biopsy of tumors of the pineal region has recently become popular particularly for those patients who do not benefit from open surgery. Biopsy can also be performed endoscopically using a flexible ventriculoscope.)
Surgical margins of primary site	7, Margins not evaluable
Scope of regional lymph node surgery	O, None (None instead of not applicable because pituitary is not one of the sites listed in FORDS to use "not applicable" for lymph node surgery.)
Radiation treatment volume	04, Brain limited
Regional treatment modality (radiation)	20, External beam, NOS
Chemotherapy	00, None
Hormone therapy	00, None
Immunotherapy	00, None
Hematologic transplant and endocrine procedures	00, None